Swiss pharmaceutical giant Novartis AG has announced significant investments of $23 billion in the United States over the next five years. This decision is driven by the company's commitment to ensure local production of key medications for American consumers. This announcement comes in the context of potential tariffs on drugs by President Donald Trump aimed at international producers.